Megakaryocyte Growth and Development Factor Is a Potent Growth Factor for Primitive Hematopoietic Progenitors in the Human Fetus

Muench, Marcus O.; Bárcena, Alicia

doi:10.1203/01.pdr.0000127020.00090.51

Cited by 8 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sorted CD34 ++ CD45 low cells were counted, washed in PBS containing 0.5% BSA, and cultured at 5 ×10 3 to 7.5 ×10 3 cells/ml in 48-well plates (Costar, Cambridge, MA) in the presence of SDM supplemented with 50 ng/ml SCF, 100 ng/ml Flt-3/Flk-2 ligand (FL), 20 ng/ml interleukin (IL)-15, 20 ng/ml IL-7 + 20 ng/ml GM-CSF + 20 ng/ml IL-3 (lymphoid-permissive conditions (Muench and Bárcena, 2001), or the combination of 50 ng/ml SCF, 100 ng/ml FL, 20 ng/ml IL-15, 20 ng/ml GM-CSF, 20 ng/ml IL-3, 20 ng/ml thrombopoietin (TPO) + 10 U/ml erythropoietin (Epo) (myelo-erythroid-megakaryocyte-permissive conditions (Muench and Bárcena, 2004)). Medium was refreshed 2×a week by changing half the volume and adding fresh cytokines.…”

Section: Methodsmentioning

confidence: 99%

Retracted: The human placenta is a hematopoietic organ during the embryonic and fetal periods of development

Bárcena

Kapidzic

Muench

et al. 2009

Developmental Biology

Self Cite

View full text Add to dashboard Cite

We studied the potential role of the human placenta as a hematopoietic organ during embryonic and fetal development. Placental samples contained two cell populations—CD34++CD45low and CD34+CD45low—that were found in chorionic villi and in the chorioamniotic membrane. CD34++CD45low cells express many cell surface antigens found on multipotent primitive hematopoietic progenitors and hematopoietic stem cells. CD34++CD45low cells contained colony-forming units culture (CFU-C) with myeloid and erythroid potential in clonogenic in vitro assays, and they generated CD56+ natural killer cells and CD19+CD20+sIgM+ B cells in polyclonal liquid cultures. CD34+CD45low cells mostly comprised erythroid- and myeloid-committed progenitors, while CD34− cells lacked CFU-C. The placenta-derived precursors were fetal in origin, as demonstrated by FISH using repeat-sequence chromosome-specific probes for X and Y. The number of CD34++CD45low cells increased with gestational age, but their density (cells per gram of tissue) peaked at 5–8 wk, decreasing more than sevenfold at the onset of the fetal phase (9 wk of gestation). In addition to multipotent progenitors, the placenta contained myeloid- and erythroid-committed progenitors indicative of active in situ hematopoiesis. These data suggest that the human placenta is an important hematopoietic organ, raising the possibility of banking placental hematopoietic stem cells along with cord blood for transplantation.

show abstract

Section: Methodsmentioning

confidence: 99%

Retracted: The human placenta is a hematopoietic organ during the embryonic and fetal periods of development

Bárcena

Kapidzic

Muench

et al. 2009

Developmental Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…After sorting, CD34 þþ CD45 low cells were counted, washed in PBS containing 0.5% BSA, and cultured at 5 Â 10 3 to 7.5 Â 10 3 cells/mL in 48-well plates (Costar, Cambridge, Mass) in the presence of SDM supplemented with 50 ng/mL SCF, 100 ng/mL FL, 20 ng/mL IL-15, 20 ng/mL IL-7, 20 ng/ mL GM-CSF, 20 ng/mL IL-3 (lymphoid-permissive conditions 21 ), or a combination of 50 ng/mL SCF, 100 ng/mL FL, 20 ng/mL IL-15, 20 ng/mL GM-CSF, 20 ng/mL IL-3, 20 ng/mL TPO, and 10 U/mL Epo (myeloerythroid-megakaryocytic-permissive conditions 23 ). Medium was refreshed twice a week by changing half the volume and adding fresh cytokines.…”

Section: Lymphoid-and Myeloerythroidmegakaryocyte Differentiation In Liquid Culturesmentioning

confidence: 99%

A New Role for the Human Placenta as a Hematopoietic Site Throughout Gestation

et al. 2009

Self Cite

View full text Add to dashboard Cite

We investigated whether the human placenta plays a role in embryonic and fetal hematopoietic development. Two cell populations—CD34++CD45low and CD34+CD45low—were found in chorionic villi. CD34++CD45low cells display many markers that are characteristic of multipotent primitive hematopoietic progenitors and hematopoietic stem cells (HSCs). Clonogenic in vitro assays showed that CD34++CD45low cells contained colony-forming units-culture (CFU-C) with myeloid and erythroid potential and differentiated into CD56+ NK cells and CD19+ B cells in culture. CD34+CD45low cells were mostly enriched in erythroid- and myeloid-committed progenitors. The number of CD34++CD45low cells increased throughout gestation in parallel with placental mass. However, their density (cells per gram of tissue) reached its peak at 5–8 weeks, decreasing more than sevenfold from the ninth week onward. In addition to multipotent progenitors, the placenta contained intermediate progenitors, indicative of active hematopoiesis. Together, these data suggest that the human placenta is potentially an important hematopoietic organ, opening the possibility of banking placental HSCs along with cord blood for transplantation.

show abstract

“…Platelets are produced within hematopoietic bone marrow from MKs that have a characteristic immunopositivity for thrombopoietin, (also known as Mpl ligand, Mpl-l, or the MK growth and development factor, MGDF), CD34, and CD38 [67,[173][174][175][176]. Flow cytometry confirmed the presence of microparticles and small CD41-positive cellular fragments in the vicinity of MKs' platelet-producing cellular prolongations.…”

Section: The Platelet's Structure and Ultrastructurementioning

confidence: 97%

Platelet-Rich Plasma in Dermatology: New Insights on the Cellular Mechanism of Skin Repair and Regeneration

Manole,

Soare,

Ceafalan

et al. 2023

Life

View full text Add to dashboard Cite

The skin’s recognised functions may undergo physiological alterations due to ageing, manifesting as varying degrees of facial wrinkles, diminished tautness, density, and volume. Additionally, these functions can be disrupted (patho)physiologically through various physical and chemical injuries, including surgical trauma, accidents, or chronic conditions like ulcers associated with diabetes mellitus, venous insufficiency, or obesity. Advancements in therapeutic interventions that boost the skin’s innate regenerative abilities could significantly enhance patient care protocols. The application of Platelet-Rich Plasma (PRP) is widely recognized for its aesthetic and functional benefits to the skin. Yet, the endorsement of PRP’s advantages often borders on the dogmatic, with its efficacy commonly ascribed solely to the activation of fibroblasts by the factors contained within platelet granules. PRP therapy is a cornerstone of regenerative medicine which involves the autologous delivery of conditioned plasma enriched by platelets. This is achieved by centrifugation, removing erythrocytes while retaining platelets and their granules. Despite its widespread use, the precise sequences of cellular activation, the specific cellular players, and the molecular machinery that drive PRP-facilitated healing are still enigmatic. There is still a paucity of definitive and robust studies elucidating these mechanisms. In recent years, telocytes (TCs)—a unique dermal cell population—have shown promising potential for tissue regeneration in various organs, including the dermis. TCs’ participation in neo-angiogenesis, akin to that attributed to PRP, and their role in tissue remodelling and repair processes within the interstitia of several organs (including the dermis), offer intriguing insights. Their potential to contribute to, or possibly orchestrate, the skin regeneration process following PRP treatment has elicited considerable interest. Therefore, pursuing a comprehensive understanding of the cellular and molecular mechanisms at work, particularly those involving TCs, their temporal involvement in structural recovery following injury, and the interconnected biological events in skin wound healing and regeneration represents a compelling field of study.

show abstract

Megakaryocyte Growth and Development Factor Is a Potent Growth Factor for Primitive Hematopoietic Progenitors in the Human Fetus

Cited by 8 publications

References 43 publications

Retracted: The human placenta is a hematopoietic organ during the embryonic and fetal periods of development

Retracted: The human placenta is a hematopoietic organ during the embryonic and fetal periods of development

A New Role for the Human Placenta as a Hematopoietic Site Throughout Gestation

Platelet-Rich Plasma in Dermatology: New Insights on the Cellular Mechanism of Skin Repair and Regeneration

Contact Info

Product

Resources

About